FR3130619A1 - Bioactive fraction isolated from roses of the Evanrat variety - Google Patents
Bioactive fraction isolated from roses of the Evanrat variety Download PDFInfo
- Publication number
- FR3130619A1 FR3130619A1 FR2113885A FR2113885A FR3130619A1 FR 3130619 A1 FR3130619 A1 FR 3130619A1 FR 2113885 A FR2113885 A FR 2113885A FR 2113885 A FR2113885 A FR 2113885A FR 3130619 A1 FR3130619 A1 FR 3130619A1
- Authority
- FR
- France
- Prior art keywords
- fraction
- skin
- supernatant
- bioactive
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 34
- 241000109329 Rosa xanthina Species 0.000 title claims abstract description 29
- 235000004789 Rosa xanthina Nutrition 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 40
- 210000003491 skin Anatomy 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 241000220317 Rosa Species 0.000 claims abstract description 10
- 235000016709 nutrition Nutrition 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000035764 nutrition Effects 0.000 claims abstract description 8
- 230000008591 skin barrier function Effects 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 230000032683 aging Effects 0.000 claims abstract description 6
- 210000004927 skin cell Anatomy 0.000 claims abstract description 6
- 230000033764 rhythmic process Effects 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000006228 supernatant Substances 0.000 claims description 24
- 238000000926 separation method Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 238000001246 colloidal dispersion Methods 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 230000001687 destabilization Effects 0.000 claims description 4
- 210000002196 fr. b Anatomy 0.000 claims description 4
- 210000003918 fraction a Anatomy 0.000 claims description 4
- 210000000540 fraction c Anatomy 0.000 claims description 4
- 238000002803 maceration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 230000037393 skin firmness Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000009759 skin aging Effects 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000001020 rhythmical effect Effects 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000036074 healthy skin Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 102000005708 Desmoglein 1 Human genes 0.000 description 2
- 108010045579 Desmoglein 1 Proteins 0.000 description 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
- 108010065038 Keratin-10 Proteins 0.000 description 2
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000007946 glucose deprivation Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108010058734 transglutaminase 1 Proteins 0.000 description 2
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 101150038243 CLOCK gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100026280 Cryptochrome-2 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 description 1
- 101000579484 Homo sapiens Period circadian protein homolog 1 Proteins 0.000 description 1
- 101000601274 Homo sapiens Period circadian protein homolog 3 Proteins 0.000 description 1
- 101001126582 Homo sapiens Post-GPI attachment to proteins factor 3 Proteins 0.000 description 1
- 102100028293 Period circadian protein homolog 1 Human genes 0.000 description 1
- 102100037630 Period circadian protein homolog 3 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention concerne un extrait de roses sous la forme d’une fraction bioactive isolée, obtenue à partir de roses fraiches de la variété Evanrat, son procédé de préparation, une composition en comprenant et ses utilisations, notamment pour favoriser et/ou améliorer la nutrition cutanée, favoriser et/ou améliorer la fonction barrière cutanée, favoriser et/ou améliorer le processus rythmique des cellules cutanées, et/ou prévenir et/ou ralentir le vieillissement de la peau.The present invention relates to a rose extract in the form of an isolated bioactive fraction, obtained from fresh roses of the Evanrat variety, its method of preparation, a composition comprising it and its uses, in particular for promoting and/or improving the skin nutrition, promoting and/or improving the skin barrier function, promoting and/or improving the rhythmic process of skin cells, and/or preventing and/or slowing down the aging of the skin.
Description
DOMAINE DE L'INVENTIONFIELD OF THE INVENTION
La présente invention concerne un extrait de roses de la variété Evanrat, aussi appelées roses ‘Jardin de Granville®’, sous la forme d’une fraction bioactive isolée, en particulier un extrait sous la forme d’une fraction bioactive isolée de pétales de roses, ainsi que son procédé de préparation. L’invention porte en outre sur une composition comprenant un extrait de roses de la variété Evanrat, ou roses ‘Jardin de Granville®’, sous la forme d’une fraction bioactive isolée selon l’invention et son utilisation pour favoriser et/ou améliorer la nutrition cutanée, la fonction barrière cutanée, le processus rythmique des cellules cutanées, prévenir et/ou ralentir le vieillissement de la peau, et par ailleurs prévenir et/ou ralentir les phénomènes de micro-inflammation chronique de la peau.The present invention relates to an extract of roses of the Evanrat variety, also called 'Jardin de Granville®' roses, in the form of an isolated bioactive fraction, in particular an extract in the form of an isolated bioactive fraction of rose petals , as well as its method of preparation. The invention further relates to a composition comprising an extract of roses of the Evanrat variety, or 'Jardin de Granville®' roses, in the form of an isolated bioactive fraction according to the invention and its use for promoting and/or improving skin nutrition, the skin barrier function, the rhythmic process of skin cells, preventing and/or slowing down the aging of the skin, and moreover preventing and/or slowing down the phenomena of chronic micro-inflammation of the skin.
ETAT DE LA TECHNIQUESTATE OF THE ART
La peau est la première barrière de protection de l'organisme vis-à-vis de l'environnement. Elle est quotidiennement soumise aux effets de facteurs d’origine exogène (ex : rayonnements UV, variations de température, pollution atmosphérique, fumée de cigarette…) ou endogène (ex : hormones…). Tous ces facteurs peuvent perturber son équilibre, notamment son équilibre micro-nutritionnel, et/ou altérer sa fonction barrière, et/ou induire un stress micro-inflammatoire et concouririn fineau vieillissement cutané.The skin is the body's first protective barrier against the environment. It is daily subject to the effects of factors of exogenous origin (eg: UV radiation, temperature variations, atmospheric pollution, cigarette smoke, etc.) or endogenous (eg, hormones, etc.). All of these factors can disturb its balance, in particular its micro-nutritional balance, and/or alter its barrier function, and/or induce micro-inflammatory stress and ultimately contribute to skin ageing.
Il est notoire que la qualité de la nutrition se reflète sur la santé de la peau et que certains désordres cutanés sont associés à des déficiences, en particulier en certains micronutriments (Park K. Role of micronutrients in skin health and function. Biomol.Ther. 2015 ; 23 ; 207-217). Les micronutriments sont essentiels au développement et à la formation de la peau, au renouvellement physiologique de l’épiderme et à l’adaptation de la peau à son environnement. Notamment, l’utilisation de vitamines (A, E, C) et/ou d’acides gras essentiels est connue dans la formulation de compositions cosmétiques destinées à la peau, en particulier pour leur effet protecteur et/ou nutritionnel.It is well known that the quality of nutrition is reflected in the health of the skin and that certain skin disorders are associated with deficiencies, in particular in certain micronutrients (Park K. Role of micronutrients in skin health and function. Biomol.Ther. 2015;23;207-217). Micronutrients are essential for the development and formation of the skin, the physiological renewal of the epidermis and the adaptation of the skin to its environment. In particular, the use of vitamins (A, E, C) and/or essential fatty acids is known in the formulation of cosmetic compositions intended for the skin, in particular for their protective and/or nutritional effect.
On connait également l’utilisation de certains extraits de roses. La demande de brevet FR3066388 de LVMH Recherche décrit notamment un extrait aqueux de roses sous la forme d’un ‘cryoextrait’ et ses effetsin vitro,en culture de kératinocytes humains, sur la stimulation de l’expression de plusieurs gènes horloge tels que CRY2, PER1 et PER3, ainsi que sur l’expression protéique de la kératine 10 (KRT10), marqueur de la maturation de l’épiderme et de la desmogléine 1 (DSG1), marqueur de la cohésion épidermique.We also know the use of certain rose extracts. Patent application FR3066388 from LVMH Research describes in particular an aqueous extract of roses in the form of a 'cryoextract' and its in vitro effects, in culture of human keratinocytes, on the stimulation of the expression of several clock genes such as CRY2 , PER1 and PER3, as well as on the protein expression of keratin 10 (KRT10), a marker of epidermal maturation, and desmoglein 1 (DSG1), a marker of epidermal cohesion.
Toutefois, il existe un besoin constant de trouver de nouveaux extraits permettant de maintenir et/ou favoriser l’équilibre nutritionnel de la peau et par conséquent de stimuler la régénération de la peau, la barrière cutanée, réduire la micro-inflammation et agir favorablement sur le vieillissement de la peau.However, there is a constant need to find new extracts which make it possible to maintain and/or promote the nutritional balance of the skin and consequently to stimulate the regeneration of the skin, the skin barrier, reduce micro-inflammation and act favorably on skin aging.
La Demanderesse a ainsi développé un nouvel extrait de roses de la variété Evanrat, ou roses ‘Jardin de Granville®’, en particulier, un nouvel extrait de pétales desdites roses, sous la forme d’une fraction bioactive isolée. De manière inattendue, la Demanderesse a mis en évidence que ce nouvel extrait sous la forme d’une « fraction sérique bioactive », aussi appelée « fraction bioactive isolée de roses » présente des effets encore améliorés par rapport à ceux déjà connus et décrits dans l’art antérieur. Notamment, l’extrait sous la forme d’une fraction bioactive isolée de roses de la variété Evanrat, ou roses ‘Jardin de Granville®’, selon l’invention améliore la nutrition cutanée en favorisant la survie cellulaire en condition de déprivation en glucose. En outre, l’extrait sous la forme d’une fraction bioactive isolée de roses selon l’invention agit sur certaines voies de signalisation, et ainsi favorise et/ou améliore la fonction barrière cutanée, favorise et/ou améliore le processus rythmique des cellules cutanées, prévient et/ou ralenti le vieillissement de la peau et prévient et/ou ralenti les phénomènes de micro-inflammation cutanée.The Applicant has thus developed a new extract from roses of the Evanrat variety, or ‘Jardin de Granville®’ roses, in particular, a new extract from the petals of said roses, in the form of an isolated bioactive fraction. Unexpectedly, the Applicant has demonstrated that this new extract in the form of a "bioactive serum fraction", also called "bioactive fraction isolated from roses" has effects that are further improved compared to those already known and described in the prior art. In particular, the extract in the form of a bioactive fraction isolated from roses of the Evanrat variety, or ‘Jardin de Granville®’ roses, according to the invention improves skin nutrition by promoting cell survival in conditions of glucose deprivation. Furthermore, the extract in the form of a bioactive fraction isolated from roses according to the invention acts on certain signaling pathways, and thus promotes and/or improves the skin barrier function, promotes and/or improves the rhythmic process of cells cutaneous, prevents and/or slows down the aging of the skin and prevents and/or slows down the phenomena of cutaneous micro-inflammation.
La présente invention porte sur un extrait de roses sous la forme d’une fraction bioactive isolée, obtenue à partir de roses fraiches de la variété Evanrat.The present invention relates to a rose extract in the form of an isolated bioactive fraction, obtained from fresh roses of the Evanrat variety.
De préférence ledit extrait de roses sous la forme d’une fraction bioactive isolée comprend au moins 500 µg/µL d’au moins un sucre monosaccharide choisi parmi le fructose, glucose et le saccharose, et/ou au moins 500 mg/Kg d’au moins un minéral choisi parmi le potassium, le calcium et le sodium.Preferably, said rose extract in the form of an isolated bioactive fraction comprises at least 500 μg/μL of at least one monosaccharide sugar chosen from fructose, glucose and sucrose, and/or at least 500 mg/Kg of at least one mineral selected from potassium, calcium and sodium.
De manière préférée, ledit extrait sous la forme d’une fraction bioactive isolée de roses selon l’invention, est caractérisé en ce que ledit extrait est obtenu à partir de pétales frais de roses de la variété Evanrat.Preferably, said extract in the form of a bioactive fraction isolated from roses according to the invention, is characterized in that said extract is obtained from fresh rose petals of the Evanrat variety.
Se préférence ledit extrait sous la forme d’une fraction bioactive isolée de roses fraiches de la variété Evanrat selon l’invention est caractérisé en ce qu’il est obtenu par un procédé comprenant les étapes :Preferably, said extract in the form of a bioactive fraction isolated from fresh roses of the Evanrat variety according to the invention is characterized in that it is obtained by a process comprising the steps:
a) nettoyage du matériel végétal, macération, pressage puis séparation mécanique du matériel végétal pour obtenir une dispersion colloïdale intracellulaire (DCI) et un matériau enrichi en fibres (fraction A) ;a) cleaning of the plant material, maceration, pressing then mechanical separation of the plant material to obtain an intracellular colloidal dispersion (INN) and a material enriched in fibers (fraction A);
b) déstabilisation du DCI avec des ondes électromagnétiques puis séparation mécanique de la dispersion colloïdale intracellulaire (DCI) pour obtenir le surnageant A et une Fraction Membranaire (fraction B) ;b) destabilization of the DCI with electromagnetic waves then mechanical separation of the intracellular colloidal dispersion (DCI) to obtain the supernatant A and a Membrane Fraction (fraction B);
c) ajustement du niveau de pH dans le surnageant A jusqu'à obtenir un pH supérieur à 6, de préférence un pH allant de 6 à 7, puis séparation mécanique du surnageant A pour obtenir le surnageant B et la fraction C (fraction cytoplasmique) ;c) adjustment of the pH level in supernatant A until a pH greater than 6 is obtained, preferably a pH ranging from 6 to 7, then mechanical separation of supernatant A to obtain supernatant B and fraction C (cytoplasmic fraction) ;
d) ajustement du niveau de pH dans le surnageant B jusqu’à obtenir un pH inférieur à 4,5 puis séparation mécanique du surnageant B pour donner une « Fraction sérique bioactive » et une fraction D (précipité) ; etd) adjustment of the pH level in supernatant B until a pH of less than 4.5 is obtained, then mechanical separation of supernatant B to give a "bioactive serum fraction" and a fraction D (precipitate); And
e) Optionnellement, mélange de la « fraction sérique bioactive » avec au moins un conservateur et/ou stabilisant.e) Optionally, mixing the “bioactive serum fraction” with at least one preservative and/or stabilizer.
La présente invention porte encore sur un procédé de préparation d’un extrait sous la forme d’une fraction bioactive isolée de roses fraiches de la variété Evanrat ou variété ‘rose Jardin de Granville®’ tel que défini dans la présente invention comprenant les étapes de :The present invention also relates to a process for the preparation of an extract in the form of a bioactive fraction isolated from fresh roses of the Evanrat variety or 'rose Jardin de Granville®' variety as defined in the present invention comprising the steps of :
a) nettoyage du matériel végétal, macération, pressage puis séparation mécanique du matériel végétal pour obtenir une dispersion colloïdale intracellulaire (DCI) et un matériau enrichi en fibres (fraction A) ;a) cleaning of the plant material, maceration, pressing then mechanical separation of the plant material to obtain an intracellular colloidal dispersion (INN) and a material enriched in fibers (fraction A);
b) déstabilisation du DCI avec des ondes électromagnétiques puis séparation mécanique de la dispersion colloïdale intracellulaire (DCI) pour obtenir le surnageant A et une Fraction Membranaire (fraction B) ;b) destabilization of the DCI with electromagnetic waves then mechanical separation of the intracellular colloidal dispersion (DCI) to obtain the supernatant A and a Membrane Fraction (fraction B);
c) ajustement du niveau de pH dans le surnageant A jusqu'à obtenir un pH supérieur à 6, de préférence un pH allant de 6 à 7, puis séparation mécanique du surnageant A pour obtenir le surnageant B et la fraction C (fraction cytoplasmique) ;c) adjustment of the pH level in supernatant A until a pH greater than 6 is obtained, preferably a pH ranging from 6 to 7, then mechanical separation of supernatant A to obtain supernatant B and fraction C (cytoplasmic fraction) ;
d) ajustement du niveau de pH dans le surnageant B jusqu’à obtenir un pH inférieur à 4,5 puis séparation mécanique du surnageant B pour donner une « Fraction sérique bioactive » et une fraction D (précipité) ; etd) adjustment of the pH level in supernatant B until a pH of less than 4.5 is obtained, then mechanical separation of supernatant B to give a "bioactive serum fraction" and a fraction D (precipitate); And
e) Optionnellement, mélange de la « fraction sérique bioactive » avec au moins un conservateur et/ou stabilisant.e) Optionally, mixing the “bioactive serum fraction” with at least one preservative and/or stabilizer.
Selon un autre aspect, la présente invention pour sur une composition pour application topique sur la peau et/ou les lèvres, en particulier la peau du visage et/ou du cou, comprenant dans un milieu physiologiquement acceptable, au moins une quantité efficace d’au moins un extrait sous la forme d’une fraction bioactive isolée de roses fraiches de la variété Evanrat tel que défini dans la présente invention.According to another aspect, the present invention for a composition for topical application to the skin and/or the lips, in particular the skin of the face and/or the neck, comprising, in a physiologically acceptable medium, at least an effective amount of at least one extract in the form of a bioactive fraction isolated from fresh roses of the Evanrat variety as defined in the present invention.
De préférence, ladite composition est caractérisée en ce que l’extrait sous la forme d’une fraction bioactive isolée de roses fraiches de la variété Evanrat est présent dans la composition en une teneur allant de 0.001 à 50%, en particulier de 0,01 à 20%, de préférence de 0,01 à 10% et de préférence encore de 0,011 à 5% en poids de matière première par rapport au poids total de ladite composition.Preferably, said composition is characterized in that the extract in the form of a bioactive fraction isolated from fresh roses of the Evanrat variety is present in the composition in a content ranging from 0.001 to 50%, in particular from 0.01 to 20%, preferably from 0.01 to 10% and more preferably from 0.011 to 5% by weight of raw material relative to the total weight of said composition.
L’invention porte également sur un procédé de traitement cosmétique de la peau et/ou des lèvres, destiné à favoriser et/ou améliorer la nutrition cutanée ; favoriser et/ou améliorer la fermeté cutanée favoriser et/ou améliorer la fonction barrière cutanée, favoriser et/ou améliorer le processus rythmique des cellules cutanées, et/ou prévenir et/ou ralentir le vieillissement de la peau, comprenant l’application sur la peau et/ou les lèvres, en particulier la peau du visage et/ou du cou, d’une composition cosmétique telle que définie dans la présente invention.The invention also relates to a method for the cosmetic treatment of the skin and/or the lips, intended to promote and/or improve skin nutrition; promote and/or improve skin firmness promote and/or improve skin barrier function, promote and/or improve rhythmic processing of skin cells, and/or prevent and/or slow skin aging, including application to the skin and/or the lips, in particular the skin of the face and/or the neck, of a cosmetic composition as defined in the present invention.
L’invention porte en outre sur l’utilisation d’au moins une quantité efficace d’au moins un extrait de sous la forme d’une fraction bioactive isolée roses fraiches de la variété Evanrat tel que défini dans la présente invention comme agent pour favoriser et/ou améliorer la nutrition cutanée ; favoriser et/ou améliorer la fermeté cutanée, favoriser et/ou améliorer la fonction barrière cutanée, favoriser et/ou améliorer le processus rythmique des cellules cutanées, prévenir et/ou ralentir le vieillissement de la peau et/ou des lèvres, en particulier la peau du visage et/ou du cou.The invention further relates to the use of at least an effective amount of at least one extract of in the form of an isolated bioactive fraction fresh roses of the variety Evanrat as defined in the present invention as an agent for promoting and/or improve skin nutrition; promote and/or improve skin firmness, promote and/or improve the skin barrier function, promote and/or improve the rhythmic process of skin cells, prevent and/or slow down the aging of the skin and/or lips, in particular the face and/or neck skin.
L’invention porte encore sur un extrait sous la forme d’une fraction bioactive isolée de roses fraiches de la variété Evanrat selon l’invention ou composition en comprenant pour son utilisation pour prévenir et/ou ralentir les phénomènes de micro-inflammation induits par un stress de la peau et/ou des lèvres, en particulier la peau du visage et/ou du cou.The invention also relates to an extract in the form of a bioactive fraction isolated from fresh roses of the Evanrat variety according to the invention or composition comprising it for its use in preventing and/or slowing down the phenomena of micro-inflammation induced by a stress of the skin and/or lips, in particular the skin of the face and/or neck.
DESCRIPTION DES FIGURESDESCRIPTION OF FIGURES
Claims (8)
a) nettoyage du matériel végétal, macération, pressage puis séparation mécanique du matériel végétal pour obtenir une dispersion colloïdale intracellulaire (DCI) et un matériau enrichi en fibres (fraction A) ;
b) déstabilisation du DCI avec des ondes électromagnétiques puis séparation mécanique de la dispersion colloïdale intracellulaire (DCI) pour obtenir le surnageant A et une Fraction Membranaire (fraction B) ;
c) ajustement du niveau de pH dans le surnageant A jusqu'à obtenir un pH supérieur à 6, de préférence un pH allant de 6 à 7, puis séparation mécanique du surnageant A pour obtenir le surnageant B et la fraction C (fraction cytoplasmique) ;
d)ajustement du niveau de pH dans le surnageant B jusqu’à obtenir un pH inférieur à 4,5 puis séparation mécanique du surnageant B pour donner une « Fraction sérique bioactive » et une fraction D (précipité) ; et
e) Optionnellement, mélange de la « fraction sérique bioactive » avec au moins un conservateur et/ou stabilisant.Rose extract in the form of an isolated bioactive fraction, obtained from fresh roses of the Evanrat variety, characterized in that it is obtained by a process comprising the steps:
a) cleaning of the plant material, maceration, pressing then mechanical separation of the plant material to obtain an intracellular colloidal dispersion (INN) and a material enriched in fibers (fraction A);
b) destabilization of the DCI with electromagnetic waves then mechanical separation of the intracellular colloidal dispersion (DCI) to obtain the supernatant A and a Membrane Fraction (fraction B);
c) adjustment of the pH level in supernatant A until a pH greater than 6 is obtained, preferably a pH ranging from 6 to 7, then mechanical separation of supernatant A to obtain supernatant B and fraction C (cytoplasmic fraction) ;
d) adjustment of the pH level in supernatant B until a pH of less than 4.5 is obtained, then mechanical separation of supernatant B to give a “bioactive serum fraction” and a fraction D (precipitate); And
e) Optionally, mixing the “bioactive serum fraction” with at least one preservative and/or stabilizer.
a) nettoyage du matériel végétal, macération, pressage puis séparation mécanique du matériel végétal pour obtenir une dispersion colloïdale intracellulaire (DCI) et un matériau enrichi en fibres (fraction A) ;
b) déstabilisation du DCI avec des ondes électromagnétiques puis séparation mécanique de la dispersion colloïdale intracellulaire (DCI) pour obtenir le surnageant A et une Fraction Membranaire (fraction B) ;
c) ajustement du niveau de pH dans le surnageant A jusqu'à obtenir un pH supérieur à 6, de préférence un pH allant de 6 à 7, puis séparation mécanique du surnageant A pour obtenir le surnageant B et la fraction C (fraction cytoplasmique) ;
d) ajustement du niveau de pH dans le surnageant B jusqu’à obtenir un pH inférieur à 4,5 puis séparation mécanique du surnageant B pour donner une « Fraction sérique bioactive » et une fraction D (précipité) ; et
e) Optionnellement, mélange de la « fraction sérique bioactive » avec au moins un conservateur et/ou stabilisant.Process for the preparation of an extract in the form of a bioactive fraction isolated from fresh roses of the Evanrat variety or 'rose Jardin de Granville®' variety as defined in any one of Claims 1 to 3, comprising the steps of:
a) cleaning of the plant material, maceration, pressing then mechanical separation of the plant material to obtain an intracellular colloidal dispersion (INN) and a material enriched in fibers (fraction A);
b) destabilization of the DCI with electromagnetic waves then mechanical separation of the intracellular colloidal dispersion (DCI) to obtain the supernatant A and a Membrane Fraction (fraction B);
c) adjustment of the pH level in supernatant A until a pH greater than 6 is obtained, preferably a pH ranging from 6 to 7, then mechanical separation of supernatant A to obtain supernatant B and fraction C (cytoplasmic fraction) ;
d) adjustment of the pH level in supernatant B until a pH of less than 4.5 is obtained, then mechanical separation of supernatant B to give a “bioactive serum fraction” and a fraction D (precipitate); And
e) Optionally, mixing the “bioactive serum fraction” with at least one preservative and/or stabilizer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2113885A FR3130619A1 (en) | 2021-12-17 | 2021-12-17 | Bioactive fraction isolated from roses of the Evanrat variety |
| PCT/FR2022/052358 WO2023111458A2 (en) | 2021-12-17 | 2022-12-14 | Bioactive fraction isolated from roses of the evanrat variety |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2113885 | 2021-12-17 | ||
| FR2113885A FR3130619A1 (en) | 2021-12-17 | 2021-12-17 | Bioactive fraction isolated from roses of the Evanrat variety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3130619A1 true FR3130619A1 (en) | 2023-06-23 |
Family
ID=82019180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2113885A Pending FR3130619A1 (en) | 2021-12-17 | 2021-12-17 | Bioactive fraction isolated from roses of the Evanrat variety |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR3130619A1 (en) |
| WO (1) | WO2023111458A2 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6130924B2 (en) | 1981-09-22 | 1986-07-17 | Matsuda Kk | |
| EP0425391A1 (en) | 1989-10-27 | 1991-05-02 | Institut Des Substances Vegetales | Compositions comprising juice and plant protoplasts, process to prepare them and their application, especially in the field of phytotherapy |
| CN1929851B (en) | 2004-01-12 | 2012-06-27 | 综合植物科技有限责任公司 | Bioactive compositions from theacea plants and processes for their production and use |
| EP2919757A1 (en) | 2012-11-14 | 2015-09-23 | Akzo Nobel Chemicals International B.V. | A method for preparing bioactive botanical compositions and the compositions made from said method |
| FR3019741A1 (en) * | 2014-04-14 | 2015-10-16 | Guangzhou Barburly Cosmetic Co Ltd | COSMETIC COMPOSITION BASED ON ROSE PETALS |
| WO2017147578A1 (en) * | 2016-02-25 | 2017-08-31 | Isp Investments Llc | Mitigating adverse effects of sunlight with ingredients obtained from living plants |
| FR3066388A1 (en) | 2017-05-16 | 2018-11-23 | L V M H Recherche | COSMETIC COMPOSITION COMPRISING ROSE EXTRACTS |
| FR3090376A1 (en) * | 2018-12-20 | 2020-06-26 | L V M H Recherche | Aqueous extract of Rose fruits as a skin neuro-protective agent |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442391B2 (en) | 2002-01-25 | 2008-10-28 | Integrated Botanical Technologies, Llc | Bioactive botanical cosmetic compositions and processes for their production |
-
2021
- 2021-12-17 FR FR2113885A patent/FR3130619A1/en active Pending
-
2022
- 2022-12-14 WO PCT/FR2022/052358 patent/WO2023111458A2/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6130924B2 (en) | 1981-09-22 | 1986-07-17 | Matsuda Kk | |
| EP0425391A1 (en) | 1989-10-27 | 1991-05-02 | Institut Des Substances Vegetales | Compositions comprising juice and plant protoplasts, process to prepare them and their application, especially in the field of phytotherapy |
| CN1929851B (en) | 2004-01-12 | 2012-06-27 | 综合植物科技有限责任公司 | Bioactive compositions from theacea plants and processes for their production and use |
| EP2491939B1 (en) | 2004-01-12 | 2017-09-20 | ISP Investments LLC | Bioactive compositions from theacea plants and processes for their production and use |
| EP2919757A1 (en) | 2012-11-14 | 2015-09-23 | Akzo Nobel Chemicals International B.V. | A method for preparing bioactive botanical compositions and the compositions made from said method |
| FR3019741A1 (en) * | 2014-04-14 | 2015-10-16 | Guangzhou Barburly Cosmetic Co Ltd | COSMETIC COMPOSITION BASED ON ROSE PETALS |
| WO2017147578A1 (en) * | 2016-02-25 | 2017-08-31 | Isp Investments Llc | Mitigating adverse effects of sunlight with ingredients obtained from living plants |
| FR3066388A1 (en) | 2017-05-16 | 2018-11-23 | L V M H Recherche | COSMETIC COMPOSITION COMPRISING ROSE EXTRACTS |
| FR3090376A1 (en) * | 2018-12-20 | 2020-06-26 | L V M H Recherche | Aqueous extract of Rose fruits as a skin neuro-protective agent |
Non-Patent Citations (5)
| Title |
|---|
| "Exceptional Regenerating Firming Mask", GNPD, MINTEL, 21 July 2017 (2017-07-21), XP002772328 * |
| DATABASE GNPD [online] MINTEL; 8 October 2020 (2020-10-08), ANONYMOUS: "La Micro-Huile de Rose Advanced Serum", XP055763239, retrieved from https://www.gnpd.com/sinatra/recordpage/8177393/ Database accession no. 8177393 * |
| KOGANOV, SOFW JOURNAL, 2017 |
| LUDIVINE RIFFAULT-VALOIS ET AL: "Complementary analytical methods for the phytochemical investigation of "Jardin de Granville", a rose dedicated to cosmetics", COMPTE RENDUS CHIMIE,, vol. 19, no. 9, 1 September 2016 (2016-09-01), pages 1101 - 1112, XP002772332, DOI: 10.1016/J.CRCI.2015.11.021 * |
| PARK K: "Role of micronutrients in skin health and function", BIOMOL.THER., vol. 23, 2015, pages 207 - 217, XP055630468, DOI: 10.4062/biomolther.2015.003 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023111458A3 (en) | 2023-08-10 |
| WO2023111458A2 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2567688B1 (en) | Use of a natural agent in cosmetic compositions | |
| EP2706980B1 (en) | Cosmetic or dermatological composition made from extracts of everlasting and use thereof | |
| JP2024050758A (en) | Cosmetic composition containing an aqueous extract of A. japonica | |
| WO2018115448A1 (en) | Cosmetic composition comprising royal jelly of the ouessant black bee | |
| EP2662072A1 (en) | Active ingredient obtained from Cichorium intybus for action on the skin barrier function similar to that of vitamin D | |
| FR3010313A1 (en) | COMPOSITION COMPRISING A GUACATONGA EXTRACT AND AROEIRA EXTRACT, USE THEREOF, AND METHOD FOR PREVENTING AND / OR TREATING SIGNS CAUSED BY SKIN AGING | |
| FR3018191A1 (en) | COSMETIC USES OF SWERTIAMARIN | |
| FR3046352A1 (en) | COSMETIC USE OF A EUTECTIC SOLVENT TO IMPROVE THE APPEARANCE OF THE SKIN | |
| FR2977491A1 (en) | COSMETIC COMPOSITION COMPRISING A MIXTURE OF HONEY | |
| FR3130619A1 (en) | Bioactive fraction isolated from roses of the Evanrat variety | |
| EP3897566A1 (en) | Rosewood extract | |
| EP3917492A1 (en) | Novel cosmetic uses of a rose extract | |
| EP2727579B1 (en) | Active ingredient for dermal application obtained from Metschnikowia agaves and uses for improving skin condition | |
| FR3078260A1 (en) | EXTRACT OF LIBER AND / OR CAMBIUM OF FAGACEAE | |
| WO2011124848A1 (en) | Use of soybean hydroxyproline-rich glycopeptides for combating the appearance of wrinkles | |
| WO2020065213A1 (en) | Use of an agave extract for enhancing the barrier function of the skin, scalp and/or mucusa and modulating the skin microbiota | |
| EP4072514A1 (en) | Cosmetic composition comprising extracts of pomegranate and peony | |
| FR3092249A1 (en) | COSMETIC ACTIVE INGREDIENT BASED ON SIMMONDSIA CHINENSIS SEED BREAD AND COSMETIC USES | |
| FR3018448A1 (en) | ACTIVE PRINCIPLE OBTAINED FROM ALGAE HYPNEA MUSCIFORMIS AND COSMETIC USES | |
| EP3817715B1 (en) | Cosmetic use of hrgp (hydroxyproline-rich glycoproteins) from ajuga reptans cells to prevent and/or combat the effects of skin ageing | |
| FR2975298A1 (en) | Use of peptides from Cynara scolymus leaves, or a hydrolyzate of Cynara scolymus leaves comprising peptides, in a cosmetic composition, which is useful for treating aging of the skin | |
| FR3141349A1 (en) | Active principle comprising cyclitols obtained from an extract of Ginkgo biloba and its cosmetic uses | |
| FR3096263A1 (en) | Cosmetic use of honey as a protective active ingredient for the skin sensory system | |
| FR3129288A1 (en) | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST ONE EXTRACT OF CYLINDROTHECA FUSIFORMIS AND AT LEAST ONE EXTRACT OF DUNALIELLA SALINA, AND COSMETIC USES THEREOF | |
| EP4248942A1 (en) | Spirodela polyrhiza extract and cosmetic uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20230623 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |